Top News
Poor Outcome for Patients With Multiple Myeloma Who Are Refractory to CD38-Targeting Agent
Human Germline Editing: Call for a Moratorium and Creation of an International Governance Framework
Prophylactic Cranial Irradiation Not Associated With Improved OS in Locally Advanced NSCLC
Tecentriq Plus Chemotherapy Approved for Initial Treatment of Extensive-Stage Small Cell Lung Cancer
Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes
Managing Neutropenic Sepsis in Patients With Cancer
Genomic Characterization of Chemoresistant Metastatic Small Cell Lung Cancer
Promising Early Results for Tisotumab Vedotin in Advanced Cervical Cancer
Adjuvant Chemotherapy Not Associated With Improved Survival in Stage I Uterine Leiomyosarcoma
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Study Concludes Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer
Finasteride has long been linked to high-grade prostate cancer, hindering its use as a chemoprevention agent. Long-term data, however, suggest no such risk exists. -
TVEC for Advanced Melanoma Yields Stunning Results in 3-Center Study
Could combining the oncolytic viral therapy TVEC with other therapies enhance the immunotherapy’s efficacy, allowing more patients to benefit? -
Genomic Profiling May Detect Lung Cancer Early
Researchers say they can distinguish between lesions that are benign and those that could become invasive — but the technology required is not yet used routinely. -
SGO 2019 Coverage
Complete coverage of the Society of Gynecologic Oncology 2019 annual meeting in Honolulu, HI. -
Multiple Myeloma and Infections: Characterizing the Risks
Despite newer agents being available to patients with multiple myeloma, the rate of infections in this patient population has remained relatively unchanged. -
Phytochemicals and Cancer
This fact sheet describes phytochemicals and the rationale behind their potential use as a chemopreventive.
More Features
Time to Treatment Discontinuation Makes Headway as Real-World End Point
An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting.
Cabozantinib a Viable Choice for Non-Clear Cell Renal Cell Carcinoma
There are no biomarkers that have been prospectively validated to help predict which patients with non-clear cell RCC might respond to cabozantinib.
BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency
The Downstream Effect of Misrepresented Clinical Trial Data
Data quality issues borne out in clinical trials don’t always reach peer reviewers, and as a result, may not reach prescribers, either.
NSAIDs in Head and Neck Cancer Bring New Meaning to Precision Medicine
Patients with PIK3CA-altered head and neck cancers lived longer if they took NSAIDs, suggesting old drugs may have new clinical uses.
